Treatment Option Overview
Treatment options for patients with mycosis fungoides and the Sézary syndrome (MF/SS) include:[1,2]
- Topical corticosteroids.
- Topical
chemotherapy with mechlorethamine (nitrogen mustard) or carmustine (BCNU).
- Psoralen and ultraviolet A radiation (PUVA).
- Ultraviolet B radiation (UVB)
- Total-skin electron-beam
radiation (TSEB).
- Radiation of symptomatic skin lesions.
- Interferon-alpha
alone or in combination with topical therapy.
- Single-agent and multiagent
chemotherapy.
- Bexarotene (topical gel or oral); retinoids.
- Denileukin diftitox (recombinant fusion protein of diptheria toxin fragments and interleukin-2 sequences).
- Combined modality treatment.
These types of treatments produce
remissions, but long-term remissions are uncommon. Treatment, therefore, is considered palliative for most patients,
though major symptomatic improvement is regularly achieved. Survival in excess of 8 years, however, is common. All patients with MF/SS are
candidates for clinical trials evaluating new approaches to treatment.
Current areas of interest in clinical trials for MF confined to the skin
include combined modality therapies containing both topical and systemic agents
such as TSEB combined with chemotherapy, topical mechlorethamine or PUVA
combined with interferon, or wide-field radiation techniques with PUVA.
Reports are available of activity for extracorporeal photochemotherapy using
psoralen; interferon-gamma or interferon-alpha; pentostatin; retinoids; fludarabine;
acyclovir; 2-chlorodeoxyadenosine; serotherapy with unlabeled,
toxin-labeled, or radiolabeled monoclonal antibodies; cell surface receptor
ligand-toxin fusion protein; and, methotrexate.[3-12]
Antigen-specific vaccination using dendritic cells [13] and ultraviolet-B phototherapy [14] are also under clinical evaluation.
References
-
Bunn PA Jr, Hoffman SJ, Norris D, et al.: Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome). Ann Intern Med 121 (8): 592-602, 1994.
[PUBMED Abstract]
-
Trautinger F, Knobler R, Willemze R, et al.: EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 42 (8): 1014-30, 2006.
[PUBMED Abstract]
-
Kaplan EH, Rosen ST, Norris DB, et al.: Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 82 (3): 208-12, 1990.
[PUBMED Abstract]
-
Heald P, Rook A, Perez M, et al.: Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. J Am Acad Dermatol 27 (3): 427-33, 1992.
[PUBMED Abstract]
-
Rosen ST, Zimmer AM, Goldman-Leikin R, et al.: Radioimmunodetection and radioimmunotherapy of cutaneous T cell lymphomas using an 131I-labeled monoclonal antibody: an Illinois Cancer Council Study. J Clin Oncol 5 (4): 562-73, 1987.
[PUBMED Abstract]
-
Foss FM, Ihde DC, Breneman DL, et al.: Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome. J Clin Oncol 10 (12): 1907-13, 1992.
[PUBMED Abstract]
-
Saven A, Carrera CJ, Carson DA, et al.: 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. Blood 80 (3): 587-92, 1992.
[PUBMED Abstract]
-
Kuzel TM, Roenigk HH Jr, Samuelson E, et al.: Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome. J Clin Oncol 13 (1): 257-63, 1995.
[PUBMED Abstract]
-
Olsen E, Duvic M, Frankel A, et al.: Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19 (2): 376-88, 2001.
[PUBMED Abstract]
-
Siegel RS, Pandolfino T, Guitart J, et al.: Primary cutaneous T-cell lymphoma: review and current concepts. J Clin Oncol 18 (15): 2908-25, 2000.
[PUBMED Abstract]
-
Duvic M, Hymes K, Heald P, et al.: Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 19 (9): 2456-71, 2001.
[PUBMED Abstract]
-
Zackheim HS, Kashani-Sabet M, McMillan A: Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients. J Am Acad Dermatol 49 (5): 873-8, 2003.
[PUBMED Abstract]
-
Maier T, Tun-Kyi A, Tassis A, et al.: Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. Blood 102 (7): 2338-44, 2003.
[PUBMED Abstract]
-
Abe M, Ohnishi K, Kan C, et al.: Ultraviolet-B phototherapy is successful in Japanese patients with early-stage mycosis fungoides. J Dermatol 30 (11): 789-96, 2003.
[PUBMED Abstract]
Back to Top
< Previous Section | Next Section > |